Schaefer, F., Al-Dakkak, I., Anokhina, K., Cohen, D., Greenbaum, L. A., & Ariceta, G. (2024). Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab. Kidney International Reports. https://doi.org/10.1016/j.ekir.2024.06.020

Schaefer, F., Al-Dakkak, I., Saval, N., Cohen, D., Greenbaum, L. A., & Ariceta, G. (2024). #243 Characteristics and safety in patients with atypical haemolytic uraemic syndrome switching to ravulizumab from eculizumab: a global registry analysis. Nephrology Dialysis Transplantation, 39(Supplement_1). https://doi.org/10.1093/ndt/gfae069.011

Fakhouri, F., Bomback, A., Kavanagh, D., Remuzzi, G., Sunder-Plassmann, G., Kanellis, J., Daina, E., Walker, P., Wang, Z., & Ahmad, Z. (2024). #1467 Pegcetacoplan for post-transplant recurrent C3 glomerulopathy or immune complex membranoproliferative glomerulonephritis in NOBLE: 12-week evolution. Nephrology Dialysis Transplantation, 39(Supplement_1). https://doi.org/10.1093/ndt/gfae069.442

Mayer, B. T., Zhang, L., deCamp, A. C., Yu, C., Sato, A., Angier, H., Seaton, K. E., Yates, N., Ledgerwood, J. E., Mayer, K., Caskey, M., Nussenzweig, M., Stephenson, K., Julg, B., Barouch, D. H., Sobieszczyk, M. E., Edupuganti, S., Kelley, C. F., McElrath, M. J., … Huang, Y. (2024). Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV. Pharmaceutics, 16(5), 594. https://doi.org/10.3390/pharmaceutics16050594

Ndife, B., Aldworth, C., Murphy, K. P., Nguyen, J., Pivneva, I., Edwards, M. L., Anderson, A., Signorovitch, J., & Canetta, P. (2024). WCN24-551 CKD PROGRESSION IN PATIENTS WITH COMPLEMENT 3 GLOMERULOPATHY (C3G) IN A US MULTI-CENTER ASSESSMENT. Kidney International Reports, 9(4), S244. https://doi.org/10.1016/j.ekir.2024.02.501

Escudero-Saiz, V. J., Gonzalez, Á., García-Herrera, A., Larque, A. B., Bomback, A. S., Morantes, L., Martínez-Chillarón, M., Ollé, J., Guillén, E., Xipell, M., Molina-Andújar, A., Rodríguez, D., Cuadrado, E., Cacho, J., Arana, C., Esforzado, N., Bastida, C., Poch, E., Diekman, F., … Blasco, M. (2024). Factor B Inhibition with Iptacopan in Recurrent C3 Glomerulopathy Following Kidney Transplant: A Report of Two Cases. Kidney Medicine, 6(6), 100823. https://doi.org/10.1016/j.xkme.2024.100823

Quintana-Gallardo, L., Bomback, A., Daina, E., Kanellis, J., Kavanagh, D., Pickering, M. C., Sunder-Plassmann, G., Walker, P., Wang, Z., Ahmad, Z., & Fakhouri, F. (2024). WCN24-683 EFFICACY OF 12-WEEK PEGCETACOPLAN IN KIDNEY TRANSPLANT RECIPIENTS WITH RECURRENT C3 GLOMERULOPATHY (C3G) OR IMMUNE COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (IC-MPGN). Kidney International Reports, 9(4), S138–S139. https://doi.org/10.1016/j.ekir.2024.02.286

Blasco, M., & Bomback, A. S. (2024). Complement and Podocytopathies: Do We Have a New Biomarker? Kidney International Reports, 9(3), 520–522. https://doi.org/10.1016/j.ekir.2024.01.037

Tarragon Estebanez, B., & Bomback, A. S. (2024). C3 Glomerulopathy: Novel Treatment Paradigms. Kidney International Reports, 9(3), 569–579. https://doi.org/10.1016/j.ekir.2023.12.007

Podos, S. D., Trachtman, H., Appel, G. B., Bomback, A. S., Dixon, B. P., Wetzels, J. F. M., Cook, H. T., Parikh, S. V., Pickering, M. C., Tumlin, J., Langman, C. B., Lightstone, L., Sperati, C. J., Daina, E., Bouman, K. P., Rice, K., Thanassi, J. A., Huang, M., Nester, C., & Remuzzi, G. (2022). Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan. American Journal of Nephrology, 53(10), 675–686. Portico. https://doi.org/10.1159/000527166

Nester, C., Appel, G. B., Bomback, A. S., Bouman, K. P., Cook, H. T., Daina, E., Dixon, B. P., Rice, K., Najafian, N., Hui, J., Podos, S. D., Langman, C. B., Lightstone, L., Parikh, S. V., Pickering, M. C., Sperati, C. J., Trachtman, H., Tumlin, J., de Vries, A. P., … Remuzzi, G. (2022). Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies. American Journal of Nephrology, 53(10), 687–700. Portico. https://doi.org/10.1159/000527167

Bomback, A. S., Kavanagh, D., Vivarelli, M., Meier, M., Wang, Y., Webb, N. J. A., Trapani, A. J., & Smith, R. J. H. (2022). Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial. Kidney International Reports, 7(10), 2150–2159. https://doi.org/10.1016/j.ekir.2022.07.004

Jones, A. V., Curtiss, D., Harris, C., Southerington, T., Hautalahti, M., Wihuri, P., Mäkelä, J., Kallionpää, R. E., Makkonen, E., Knopp, T., Mannermaa, A., Mäkinen, E., Moilanen, A.-M., Tezel, T. H., & Waheed, N. K. (2022). An assessment of prevalence of Type 1 CFI rare variants in European AMD, and why lack of broader genetic data hinders development of new treatments and healthcare access. PLOS ONE, 17(9), e0272260. https://doi.org/10.1371/journal.pone.0272260

Xu, Y., Zhou, Z., Brooks, B., Ferguson, T., Obliosca, J., Huang, J., Kaneko, I., Iwanaga, S., Yuda, M., Tsuji, Y., Zhang, H., Luo, C. C., Jiang, X., Kong, X.-P., Tsuji, M., & Tison, C. K. (2022). Layer-by-Layer Delivery of Multiple Antigens Using Trimethyl Chitosan Nanoparticles as a Malaria Vaccine Candidate. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.900080

Lomax-Browne, H. J., Medjeral-Thomas, N. R., Barbour, S. J., Gisby, J., Han, H., Bomback, A. S., Fervenza, F. C., Cairns, T. H., Szydlo, R., Tan, S.-J., Marks, S. D., Waters, A. M., Appel, G. B., D’Agati, V. D., Sethi, S., Nast, C. C., Bajema, I., Alpers, C. E., Fogo, A. B., … Pickering, M. C. (2022). Association of Histologic Parameters with Outcome in C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis. Clinical Journal of the American Society of Nephrology, 17(7), 994–1007. https://doi.org/10.2215/cjn.16801221

Smith, R., Kavanagh, D., Tawfiq, R., Trapani, A. J., Wang, Y., Webb, N. J., Meier, M., Vivarelli, M., & Bomback, A. (2022). POS-038 ALTERNATIVE COMPLEMENT PATHWAY INHIBITION WITH IPTACOPAN TO ARREST DISEASE PROGRESSION IN C3 GLOMERULOPATHY (APPEAR-C3G): A PHASE 3 STUDY. Kidney International Reports, 7(6), S454–S455. https://doi.org/10.1016/j.ekir.2022.04.060

Rashidi, A., Shah, C., & Sekulic, M. (2022). The Role of Kidney Biopsy in Immune Checkpoint Inhibitor-Associated AKI. Kidney360, 3(3), 530–533. https://doi.org/10.34067/kid.0000232022

Bomback, A., Herlitz, L. C., Yue, H., Kedia, P. P., Schall, T. J., & Bekker, P. (2022). POS-112 EFFECT OF AVACOPAN, A SELECTIVE C5A RECEPTOR INHIBITOR, ON COMPLEMENT 3 GLOMERULOPATHY HISTOLOGIC INDEX OF DISEASE CHRONICITY. Kidney International Reports, 7(2), S47–S48. https://doi.org/10.1016/j.ekir.2022.01.124

Thangaraju, K., Katneni, U., Akpan, I. J., Tanaka, K., Thomas, T., Setua, S., Reisz, J. A., Cendali, F., Gamboni, F., Nemkov, T., Kahn, S., Wei, A. Z., Valk, J. E., Hudson, K. E., Roh, D. J., Moriconi, C., Zimring, J. C., D’Alessandro, A., Spitalnik, S. L., … Buehler, P. W. (2022). The Impact of Age and BMI on the VWF/ADAMTS13 Axis and Simultaneous Thrombin and Plasmin Generation in Hospitalized COVID-19 Patients. Frontiers in Medicine, 8. https://doi.org/10.3389/fmed.2021.817305

Lee, W., Zernant, J., Su, P.-Y., Nagasaki, T., Tsang, S. H., & Allikmets, R. (2022). A genotype-phenotype correlation matrix for ABCA4 disease based on long-term prognostic outcomes. JCI Insight, 7(2). https://doi.org/10.1172/jci.insight.156154